Successful inclusion in Phase 2 of LiPlaCis® for metastatic Breast cancer
Hoersholm, Denmark September 29th 2017 – Oncology Venture Sweden AB (OV:ST) announces that today 12 metastatic breast cancer patients have been successfully included in the phase 2 part of the LiPlaCis for metastatic breast cancer. As previously announced we expected to include 12-15 patients by Q3 2017. The initial good clinical results have led Oncology Venture to continue the trial and the company has been allowed to expand the number of patients to up to 20 patients. The company has increased the inclusion from the top 20% sensitive patients to include the top 2/3 of patients. This has